Zou Bin

Zou Bin is a seasoned executive and has helmed many leadership positions. He is currently an Adjunct Associate Professor at both National University of Singapore and Nanyang Technological University. Previously, he served as Managing Director at Trinity Innovation Bioventure Singapore (TIBS) and was the CEO of Shanghai Blueray Biopharma where he successfully led the team to develop several candidates into investigational new drug (IND) stage. Prior to his venture, Dr. Zou was a Principal Scientist at Novartis Institute for Tropical Disease where he spearheaded the team to the discovery of Phase II clinical trials drug NITD609. He is the author to more than 25 peer reviewed publications.

Zou Bin holds a Ph.D. from Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences and graduated with a B.S in Chemistry from Nankai University.